Last reviewed · How we verify
Lopremone (PROTIRELIN)
Lopremone (Protirelin) is a small molecule drug that targets the thyrotropin-releasing hormone receptor. Originally developed by, it is currently owned by and was FDA approved in 1976 for Diagnostic Test for Thyroid Dysfunction and Pituitary Function Studies. As an off-patent drug, it is not commercially available as a generic. Key safety considerations include its low bioavailability of 2%. Lopremone is used to assess thyroid function and pituitary gland activity.
At a glance
| Generic name | PROTIRELIN |
|---|---|
| Drug class | protirelin |
| Target | Thyrotropin-releasing hormone receptor |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Diagnostic Test for Thyroid Dysfunction
- Pituitary Function Studies
Common side effects
Key clinical trials
- Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer (PHASE1)
- Mechanistic Study of Subclinical Hypothyroidism In the Elderly (NA)
- A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities (PHASE2)
- Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue (PHASE2)
- Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3
- A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopremone CI brief — competitive landscape report
- Lopremone updates RSS · CI watch RSS